Gilead Sciences Inc. made a “responsible” pricing decision for its remdesivir based on currently available information about its usefulness in treating COVID-19, the US Institute for Clinical and Economic Review said in a statement released 29 June.
Gilead has announced the drug will cost $390 per vial for government payers in developed countries and $520 for commercial payers in the US. That translates to a cost of $2,340 for governments and $3,120 for US health plans for a six-vial, five-day course of treatment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?